Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Emisphere Technologies has reported encouraged findings from a clinical study assessing the oral delivery of GLP-1 peptide safely and effectively.
Subscribe to our email newsletter
The study, conducted in 16 healthy male subjects, was designed to explore the pharmacodynamic effects of a single oral dose of GLP-1 administered 15 minutes prior to an oral glucose tolerance test. The study used a delivery-agent-based approach using Emisphere’s Eligen technology, and was conducted at University Hospital in Basel, Switzerland.
For the study, GLP-1 was formulated as a tablet with Emisphere’s delivery agent known as SNAC. The study also showed that pharmacological levels were achieved after a 2mg oral dose. The study demonstrated that the oral formulation of GLP-1 stimulated an early increase in fasting insulin and a decrease in fasting glucose as compared to placebo.
Emisphere’s Eligen technology is based on the development of small organic molecules, termed delivery agents or carriers, which interact non-covalently with macromolecules to enable their oral absorption.
Michael Novinski, president and CEO of Emisphere, said: “The study provides yet further evidence in the application of our Eligen technology as a potential solution to critical hurdles in pharmaceutical development. Hopefully, its use with GLP-1 in the treatment of diabetes will improve healthcare for millions of patients.”